402 related articles for article (PubMed ID: 8675638)
1. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
Wallace JL; McKnight W; Del Soldato P; Baydoun AR; Cirino G
J Clin Invest; 1995 Dec; 96(6):2711-8. PubMed ID: 8675638
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans.
Fiorucci S; Mencarelli A; Meneguzzi A; Lechi A; Renga B; del Soldato P; Morelli A; Minuz P
J Am Coll Cardiol; 2004 Aug; 44(3):635-41. PubMed ID: 15358033
[TBL] [Abstract][Full Text] [Related]
3. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat.
Carini M; Aldini G; Orioli M; Piccoli A; Rossoni G; Maffei Facino R
Life Sci; 2004 May; 74(26):3291-305. PubMed ID: 15094329
[TBL] [Abstract][Full Text] [Related]
6. Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin.
Takeuchi K; Ukawa H; Konaka A; Kitamura M; Sugawa Y
J Pharmacol Exp Ther; 1998 Jul; 286(1):115-21. PubMed ID: 9655849
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study.
Fiorucci S; Santucci L; Gresele P; Faccino RM; Del Soldato P; Morelli A
Gastroenterology; 2003 Mar; 124(3):600-7. PubMed ID: 12612897
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.
Gresele P; Momi S
Cardiovasc Drug Rev; 2006; 24(2):148-68. PubMed ID: 16961726
[TBL] [Abstract][Full Text] [Related]
9. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
Momi S; Impagnatiello F; Guzzetta M; Caracchini R; Guglielmini G; Olivieri R; Monopoli A; Gresele P
Eur J Pharmacol; 2007 Sep; 570(1-3):115-24. PubMed ID: 17632098
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
[TBL] [Abstract][Full Text] [Related]
11. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016).
Corazzi T; Leone M; Maucci R; Corazzi L; Gresele P
J Pharmacol Exp Ther; 2005 Dec; 315(3):1331-7. PubMed ID: 16144976
[TBL] [Abstract][Full Text] [Related]
12. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production.
Lechi C; Andrioli G; Gaino S; Tommasoli R; Zuliani V; Ortolani R; Degan M; Benoni G; Bellavite P; Lechi A; Minuz P
Thromb Haemost; 1996 Nov; 76(5):791-8. PubMed ID: 8950792
[TBL] [Abstract][Full Text] [Related]
13. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a unique dihydropyrimidinone, ethyl 4-(4'-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model.
Priya N; Singh P; Bhatia S; Medhi B; Prasad AK; Parmar VS; Raj HG
J Pharm Pharmacol; 2011 Sep; 63(9):1175-85. PubMed ID: 21827490
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.
Harmon S; Inkielewicz-Stepniak I; Jones M; Ledwidge M; Santos-Martinez MJ; Medina C; Radomski MW; Gilmer JF
J Pharm Pharmacol; 2012 Jan; 64(1):77-89. PubMed ID: 22150675
[TBL] [Abstract][Full Text] [Related]
16. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia.
Derhaschnig U; Schweeger-Exeli I; Marsik C; Cardona F; Minuz P; Jilma B
Platelets; 2010; 21(5):320-8. PubMed ID: 20608787
[TBL] [Abstract][Full Text] [Related]
17. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication.
Gresele P; Migliacci R; Procacci A; De Monte P; Bonizzoni E
Thromb Haemost; 2007 Mar; 97(3):444-50. PubMed ID: 17334512
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo.
Pircher J; Fochler F; Czermak T; Mannell H; Kraemer BF; Wörnle M; Sparatore A; Del Soldato P; Pohl U; Krötz F
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2884-91. PubMed ID: 23023375
[TBL] [Abstract][Full Text] [Related]
19. Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester].
Wallace JL; Muscará MN; de Nucci G; Zamuner S; Cirino G; del Soldato P; Ongini E
J Pharmacol Exp Ther; 2004 May; 309(2):626-33. PubMed ID: 14755007
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
